Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

AIMS: To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid sequences, in patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM). METHODS...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Diabetes Obes Metab
Prif Awduron: Ilag, L. L., Deeg, M. A., Costigan, T., Hollander, P., Blevins, T. C., Edelman, S. V., Konrad, R. J., Ortmann, R. A., Pollom, R. K., Huster, W. J., Zielonka, J. S., Prince, M. J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2016
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737399/
https://ncbi.nlm.nih.gov/pubmed/26434665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12584
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg